Sentynl Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sentynl Therapeutics, Inc.
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
CMS and FDA data showed prescriptions jumping while other fentanyl products were coming down.
Biomarker diagnostics are the linchpin of personalized medicine. But building a successful business around such tests is anything but straightforward, given the complexities associated with both their development and commercialization. Today's molecular diagnostic companies need to think carefully before they choose a "go it alone" strategy when developing a particular test. It may make more sense to forge a partnership with another diagnostic company or a drug developer with the goal of sharing costs and relative risks.
J&J isn't the ground-shaker in molecular testing that Roche Diagnostics is--so it is forging a different path to becoming a leader in emerging high-potential sectors of the in vitro diagnostics industry. It formed a subsidiary Veridex, dedicated to cancer diagnostics. That subsidiary is assembling a platform of core technologies and recently completed several deals, including in-licensing prostate cancer markers based on methylation, a hot area of research, from start-up Oncomethylome Sciences.
- Specialty Pharmaceuticals